• Hero Banner
  • ACVCACVC
  • DVM 360
  • Fetch DVM 360Fetch DVM 360
DVM 360
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
By Role
AssociatesOwnersPractice ManagerStudentsTechnicians
Subscriptions
dvm360 Newsletterdvm360 Magazine
News
All News
Association
Breaking News
Education
Equine
FDA
Law & Ethics
Market Trends
Medical
Products
Recalls
Regulatory
Digital Media
dvm360 LIVE!™
Expert Interviews
The Vet Blast Podcast
Medical World News
Pet Connections
The Dilemma Live
Vet Perspectives™
Weekly Newscast
dvm360 Insights™
Publications
All Publications
dvm360
Firstline
Supplements
Top Recommended Veterinary Products
Vetted
Clinical
All Clinical
Anesthesia
Animal Welfare
Behavior
Cardiology
CBD in Pets
Dentistry
Dermatology
Diabetes
Emergency & Critical Care
Endocrinology
Equine Medicine
Exotic Animal Medicine
Feline Medicine
Gastroenterology
Imaging
Infectious Diseases
Integrative Medicine
Nutrition
Oncology
Ophthalmology
Orthopedics
Pain Management
Parasitology
Pharmacy
Surgery
Toxicology
Urology & Nephrology
Virtual Care
Business
All Business
Business & Personal Finance
Buying or Selling a Practice
Hospital Design
Leadership & Personal Growth
Personnel Management
Practice Finances
Practice Operations
Technology
Wellbeing & Lifestyle
Continuing Education
Conferences
Live Conferences
Conference News
Conference Proceedings
Resources
CBD in Pets
Contests
Veterinary Heroes
Partners
Spotlight Series
Team Meeting in a Box
Toolkit
Top Recommended Veterinary Products
Vet to Vet
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us

© 2023 MJH Life Sciences and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Advertisement
By Role
  • Associates
  • Owners
  • Practice Manager
  • Students
  • Technicians
Subscriptions
  • dvm360 Newsletter
  • dvm360 Magazine
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us
  • MJHLS Brand Logo

© 2023 MJH Life Sciences™ and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Elanco Animal Health to acquire Aratana Therapeutics

April 27, 2019
dvm360, dvm360 June 2019, Volume 50, Issue 6

Two veterinary companies with a successful working history are set to become one.

Since its founding in 2010, Kansas-based Aratana Therapeutics has become a major player in the animal health industry. Elanco Animal Health, a subsidiary of Eli Lilly and Co., has been a player for more than 60 years. Today, the companies announced that Aratana will be acquired by Elanco for $245 million.

The two companies have a history together. In 2016, Elanco agreed to pay Aratana $45 million to develop, manufacture and commercialize the canine osteoarthritis drug Galliprant (grapiprant).

According to company press releases, the deal is structured as a stock-for-stock transaction, with Aratana shareholders receiving 0.1481 share of Elanco stock and one contingent value right for each share of Aratana stock if the inappetence drug Entyce (capromorelin) achieves certain sales levels before the end of 2021. That results in a premium of about 40% on Aratana's current share price. The deal is contingent on Aratana shareholder approval and antitrust considerations.

Advertisement

Aratana has won regulatory approval for four drugs for use in companion animals, with the most recent, Nocita (bupivacaine liposome injectable solution), being approved in 2018. The company currently has several additional pipeline products in development for conditions ranging from atopic dermatitis and pain/inflammation to oncology.

“Aratana has been one of the most innovative startups in animal health, bringing breakthrough solutions to the market,” said Jeff Simmons, Elanco's president and CEO, in a company press release. “We look forward to putting greater energy behind these brands with our increased share of voice in the field while leveraging Aratana's strong presence in the specialty market. ... We believe the deal would bring greater value to veterinarians and pet owners, as well as both Elanco and Aratana shareholders.”

Earlier this year, Aratana founder Steven St. Peter resigned as CEO of the company. He is succeeded by Craig Tooman as president and CEO.

“This proposed transaction acknowledges Aratana's contribution of pet therapeutics to the animal health industry, specifically recognizing our strong track record as a drug developer and our field team's unmatched expertise delivering innovation to veterinary specialists,” Tooman said in the Aratana release.

The deal is expected to be finalized midyear. Aratana's board has already approved it unanimously.

 

download issueDownload Issue: dvm360 June 2019

Related Content:

ProductsBreaking Newsdvm360 June 2019
New Automatic 2-in-1 Pet Feeder and Water Dispenser launched
New Automatic 2-in-1 Pet Feeder and Water Dispenser launched
dvm360® product report: One Health microsite, plus mushroom equine supplement and more
dvm360® product report: One Health microsite, plus mushroom equine supplement and more
dvm360® product report: ear dehumidifier, plus dental artificial intelligence and more
dvm360® product report: ear dehumidifier, plus dental artificial intelligence and more

Advertisement

Latest News

Drug for acute onset of canine pancreatitis is launched on the US market

New Automatic 2-in-1 Pet Feeder and Water Dispenser launched

PetHub launches AI tools for pet owners

Prairie dog pups emerge from underground at Maryland Zoo

View More Latest News
Advertisement